- Acumen Powered by Robins Kaplan LLP®
- Affirmative Recovery
- American Indian Law and Policy
- Antitrust and Trade Regulation
- Appellate Advocacy and Guidance
- Business Litigation
- Civil Rights and Police Misconduct
- Class Action Litigation
- Commercial/Project Finance and Real Estate
- Corporate Governance and Special Situations
- Corporate Restructuring and Bankruptcy
- Domestic and International Arbitration
- Entertainment and Media Litigation
- Health Care Litigation
- Insurance and Catastrophic Loss
- Intellectual Property and Technology Litigation
- Mass Tort Attorneys
- Medical Malpractice Attorneys
- Personal Injury Attorneys
- Telecommunications Litigation and Arbitration
- Wealth Planning, Administration, and Fiduciary Disputes
Acumen Powered by Robins Kaplan LLP®
Ediscovery, Applied Science and Economics, and Litigation Support Solutions
-
September 10, 2024Robins Kaplan Ranks Among Top Firms In 2024 American Lawyer Mid-Level Associates Survey
-
September 9, 2024Federal Judge Orders Transformative Reforms at West LA VA Campus in Major Victory for Disabled Veterans
-
September 9, 2024Robins Kaplan Partners Named to 2025 Lawdragon 500 Leading Litigators in America Guide
-
September 27, 2024Minnesota’s Largest Patent Jury Verdict: The Inside Story
-
October 9, 2024Perception vs. Reality in Trust and Estate Matters:
-
October 20, 2024License Agreement Disputes:
-
September 2024Q&A with Alan Harter, Founder of Pactolus Private Wealth Management
-
August 2024Recruiting & Retaining Diverse Attorneys: Building an Inclusive Legal Profession
-
August 22, 2024Prior Art Takeaways From Fed. Circ. Public Disclosure Ruling
-
September 16, 2022Uber Company Systems Compromised by Widespread Cyber Hack
-
September 15, 2022US Averts Rail Workers Strike With Last-Minute Tentative Deal
-
September 14, 2022Hotter-Than-Expected August Inflation Prompts Massive Wall Street Selloff
Find additional firm contact information for press inquiries.
Find resources to help navigate legal and business complexities.
In re Lamictal Direct Purchaser Antitrust Litigation
Where a settlement agreement that resolves a Hatch-Waxman patent litigation does not include a reverse payment, the Supreme Court’s FTC v. Actavis analysis is inapplicable.
Spring 2014
Case Name: In re Lamictal Direct Purchaser Antitrust Litigation, Case No. 12-cv-995 (WHW), 2014 U.S. Dist. LEXIS 9257 (D.N.J. Jan. 24, 2014) (Walls, J.)
Drug Product and Patent(s)-in-Suit: Lamictal® (lamotrigine); U.S. Patent No. 4,602,017 (“the ’017 patent”)
Nature of the Case and Issue(s) Presented: Plaintiff filed a suit challenging a settlement between GlaxoSmithKline and Teva, which was entered into for purposes of resolving those parties patent litigation concerning the ’017 patent. In relevant part, the settlement agreement provided Teva with an exclusivity period of 37 months for chewable Lamictal and six months exclusivity for Lamictal tablets. GSK also agreed not to launch its own authorized generic drug product during these exclusivity periods. The district court originally found that because the settlement agreement did not involve a transfer of money, it “[was] not subject to antitrust scrutiny” and dismissed the case for failure to state a claim. The case was remanded in light of the Supreme Court’s decision in FTC v. Actavis.
The issue before the court was whether the settlement agreement was subject to the “rule of reason” antitrust analysis provided in Actavis. Plaintiff argued that this analysis should apply even though there was no monetary payment from GSK because Teva gained significant financial benefit from the agreement. Defendants argued that Actavis does not apply because there was no payment, and the factors in Actavis favor dismissal.
Why Defendants Prevailed: The court affirmed its dismissal of the complaint because the scrutiny in Actavis only applies to settlement agreements that include reverse payments. The court reasoned that Actavis only applied in cases where monetary payments were made because the Supreme Court almost always referred to the issue as one involving payments of money. As there was no payment in the settlement agreement here, the Actavis scrutiny was inapplicable.
The court also considered whether the non-payment benefits obtained by Teva in the agreement could fall within the purview of the Actavis holding. The court concluded that such non-monetary benefits did not trigger the Actavis scrutiny because those benefits were necessary for adequate consideration to be present to create an enforceable settlement agreement. The court also noted that other courts considering the issue have similarly applied the Actavis scrutiny in a more limited manner, i.e., when a monetary payment is included as part of the settlement.
Even if the “rule of reason” analysis were to apply, the court found that the five factors weighed in favor of defendants. The court did not find adverse impact on competition because the exclusivity period was short, six months for chewables. The court also noted that the early entry of the generic during the life of the patent was a significant fact in favor of upholding the settlement.
Related Publications
Related News
If you are interested in having us represent you, you should call us so we can determine whether the matter is one for which we are willing or able to accept professional responsibility. We will not make this determination by e-mail communication. The telephone numbers and addresses for our offices are listed on this page. We reserve the right to decline any representation. We may be required to decline representation if it would create a conflict of interest with our other clients.
By accepting these terms, you are confirming that you have read and understood this important notice.